Anitoa CMOS Sensor Powers Rapid Nucleic Acid Test for New Coronavirus

PRNewswire: Anitoa has demonstrated a solution for rapid on-site nucleic acid test of the 2019 novel coronavirus (2019-nCoV). Anitoa combines a high performance ultra-portable Real Time Polymerase Chain Reaction (qPCR) instrument called Maverick, with an innovative "one-step" reverse transcription qPCR (RT-qPCR) reagent for testing 2019-nCoV.

Maverick is powered by a unique CMOS biosensor chip developed by Anitoa. The CMOS biosensor integrates many sensing and processing functions necessary for qPCR in a single silicon chip, thus significantly reducing the footprint and cost of the device.

Having a R&D center in Hangzhou China, Anitoa tested its solution in hospitals and CDC-labs of China with actual patient samples. Early test results with Maverick solution showed a 97% accuracy, with 99% specificity.

"We are encouraged by the very promising performance results of the Maverick solution in detecting the 2019 new coronavirus. We want to contribute everything we have to help fight and prevent the spread of this terrible and deadly disease," says Zhimin Ding, CEO of Anitoa Systems.